文章：

了解和解决基于腺病毒的卵巢癌病毒治疗成功的障碍

Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer 

原文发布日期：2020-09-19 

英文摘要：

Ovarian cancer is the leading cause of death among women with gynecological cancer, with an overall 5-year survival rate below 50% due to a lack of specific symptoms, late stage at time of diagnosis and a high rate of recurrence after standard therapy. A better understanding of heterogeneity, genetic mutations, biological behavior and immunosuppression in the tumor microenvironment have allowed the development of more effective therapies based on anti-angiogenic treatments, PARP and immune checkpoint inhibitors, adoptive cell therapies and oncolytic vectors. Oncolytic adenoviruses are commonly used platforms in cancer gene therapy that selectively replicate in tumor cells and at the same time are able to stimulate the immune system. In addition, they can be genetically modified to enhance their potency and overcome physical and immunological barriers. In this review we highlight the challenges of adenovirus-based oncolytic therapies targeting ovarian cancer and outline recent advances to improve their potential in combination with immunotherapies. 

摘要翻译： 

卵巢癌是妇科癌症患者死亡的主要原因，由于缺乏特异性症状、诊断时多为晚期以及标准治疗后复发率高，其总体五年生存率低于50%。随着对肿瘤异质性、基因突变、生物学行为以及肿瘤微环境中免疫抑制机制的深入理解，基于抗血管生成治疗、PARP及免疫检查点抑制剂、过继性细胞疗法和溶瘤病毒载体的更有效疗法得以发展。溶瘤腺病毒是癌症基因治疗中常用的载体平台，能选择性地在肿瘤细胞中复制，同时刺激免疫系统。此外，通过基因修饰可增强其效力并克服物理与免疫屏障。本文重点探讨针对卵巢癌的腺病毒溶瘤疗法面临的挑战，并概述其与免疫疗法联合应用的最新进展。

原文链接：

Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer